SCHEMBL9890668

SCHEMBL9890668

O=C(O)Cc1ccc(Cl)cc1-c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PTGDR2 Q9Y5Y4 3/20 0.49
CXCL8 P10145 3/20 0.46
CHRM1 P11229 2/20 0.46
CYP2C9 P11712 1/20 0.46
GCGR P47871 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.43
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM3 P20309 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890650 0.88 LMNA (0.51) LMNASMN1; SMN2PTGDR2CXCL8CHRM1
SCHEMBL2394194 0.87 L3MBTL1 (0.46) LMNASMN1; SMN2PTGDR2CHRM1GCGR
SCHEMBL9890652 0.84 CXCL8 (0.50) CXCL8
SCHEMBL2395234 0.83 CNR1 (0.43) LMNASMN1; SMN2CHRM1GCGRCHRM2
SCHEMBL538984 0.82 CXCL8 (0.57) LMNAPTGDR2CXCL8
SCHEMBL5429296 0.81 PTGDR2 (0.56) PTGDR2CXCL8CHRM1CYP2C9SUCNR1
SCHEMBL9890678 0.81 CXCL8 (0.49) LMNASMN1; SMN2CXCL8FABP4FABP5
SCHEMBL348979 0.79 KEAP1 (0.50) CXCL8CHRM1CYP2C9KEAP1NFE2L2
SCHEMBL29434734 0.79 KEAP1 (0.50) CXCL8CHRM1CYP2C9KEAP1NFE2L2
SCHEMBL9890665 0.77 CYP1A2 (0.57) LMNAPTGDR2CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 LMNA 3980/4885SMN1; SMN2 2980/4885PTGDR2 1062/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 LMNA 3980/4885SMN1; SMN2 2980/4885PTGDR2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.